Table 3. Relationship between worst pain and main baseline characteristics (n=1021).
|
Number of patients (%) |
|||||
|---|---|---|---|---|---|
| Not at all | A little | Quite a bit | Very much | ||
| 269 (26) | 433 (42) | 245 (24) | 74 (7) | ||
| Clinical trial | <0.001a | ||||
| ELVIS | 26 (19) | 67 (50) | 35 (26) | 7 (5) | |
| MILES | 171 (30) | 238 (42) | 123 (22) | 29 (5) | |
| GEMVIN | 72 (22) | 128 (39) | 87 (27) | 38 (12) | |
| Age | <0.001a | ||||
| <70 years | 73 (22) | 129 (39) | 90 (27) | 38 (12) | |
| ⩾70 years | 196 (28) | 304 (44) | 155 (22) | 36 (5) | |
| Gender | 0.69b | ||||
| Male | 221 (26) | 363 (43) | 205 (24) | 56 (7) | |
| Female | 48 (27) | 70 (40) | 40 (23) | 18 (10) | |
| Performance status | <0.001b | ||||
| 0–1 | 241 (29) | 364 (43) | 187 (22) | 53 (6) | |
| 2 | 28 (16) | 69 (39) | 58 (33) | 21 (12) | |
| Stage | <0.001b | ||||
| IIIB | 89 (31) | 136 (47) | 50 (17) | 13 (5) | |
| IV | 180 (25) | 297 (41) | 195 (27) | 61 (8) | |
| Bone metastases | <0.001b | ||||
| Absent | 249 (31) | 347 (44) | 164 (21) | 36 (4) | |
| Present | 20 (9) | 86 (38) | 81 (36) | 38 (17) | |
a
Kruskal–Wallis test.
b
Wilcoxon rank-sum test stratified by clinical trial.